PBA
GPCR icon

Paradigm Biocapital Advisors’s Structure Therapeutics GPCR Stock Holding History

Paradigm Biocapital Advisors’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.3M Buy
+545,287
New +$37.3M 0.54% 30
2025
Q4 		– Sell
-372,869
Closed -$10.4M – 37
2025
Q3 		$10.4M Buy
+372,869
New +$7.43M 0.3% 35

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Paradigm Biocapital Advisors's GPCR Position: Q1 2026 in Review

Paradigm Biocapital Advisors opened a new position in Structure Therapeutics (GPCR) in Q1 2026: 545,287 shares worth $26.3M. The stake represents 0.54% of the portfolio and ranks #30 among its holdings. This is a return to the name: Paradigm Biocapital Advisors previously reported a position in GPCR as recently as Q3 2025.

Paradigm Biocapital Advisors first reported a position in GPCR in Q3 2025 and has held it in 2 quarters since. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Paradigm Biocapital Advisors held 545,287 shares of Structure Therapeutics worth $26.3M as of Q1 2026.
  • Structure Therapeutics was a new Paradigm Biocapital Advisors position in Q1 2026.
  • Structure Therapeutics made up 0.54% of Paradigm Biocapital Advisors's portfolio in Q1 2026, its #30 holding.
  • Paradigm Biocapital Advisors first reported a position in Structure Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2026, filed 15 May 2026.